Effective Test For Cervical Cancer Screening.
An HPV examine recently approved by US fitness officials is an effective way to check for cervical cancer, two outstanding women's health organizations said Thursday. The groups said the HPV exam is an effective, one-test alternative to the current recommendation of screening with either a Pap examination alone or a combination of the HPV test and a Pap test. However, not all experts are in agreement with the move: the largest ob-gyn alliance in the United States, the American College of Obstetricians and Gynecologists (ACOG) is still recommending that women grey 30 to 65 be screened using either the Pap test alone, or "co-tested" with a coalition of both the HPV test and a Pap test. The new, so-called interim auspices report was issued by two other groups - the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.
It followed US Food and Drug Administration authorization last year of the cobas HPV probe as a primary test for cervical cancer screening. The HPV try detects DNA from 14 types of HPV - a sexually transmitted virus that includes types 16 and 18, which cause 70 percent of cervical cancers. The two medical groups said the interim regulation make public will help health care providers draw how best to include primary HPV testing in the care of their female patients until a number of medical societies update their guidelines for cervical cancer screening.
And "Our examination of the data indicates that leading HPV testing misses less pre-cancer and cancer than cytology a Pap test alone. The government panel felt that primary HPV screening can be considered as an option for women being screened for cervical cancer," interim direction report lead author Dr Warner Huh said in a newsflash release from the Society of Gynecologic Oncology. Huh is director of the University of Alabama's Division of Gynecologic Oncology The FDA approved the cobas HPV assay continue April as a first step in cervical cancer screening for women aged 25 and older.
Roche Molecular Systems Inc, headquartered in Pleasanton, California, makes the test. Thursday's interim communication recommends that fundamental HPV testing should be considered starting at age 25. For women younger than 25, tendency guidelines recommending a Pap test solo beginning at age 21 should be followed. The new recommendations also state that women with a negative development for a primary HPV test should not be tested again for three years, which is the same interval recommended for a normal Pap check result.
Wednesday 25 March 2015
Some Chemicals Have Harmful Effects On Ovarian Function
Some Chemicals Have Harmful Effects On Ovarian Function.
Extensive acquaintance to cheap chemicals appears to be linked to an earlier start of menopause, a new workroom suggests. Researchers found that menopause typically begins two to four years earlier in women whose bodies have intoxication levels of certain chemicals found in household items, personal care products, plastics and the environment, compared to women with diminish levels of the chemicals. The investigators identified 15 chemicals - nine (now banned) PCBs, three pesticides, two forms of plastics chemicals called phthalates, and the toxin furan - that were significantly associated with an earlier move of menopause and that may have unhealthy slang shit on ovarian function.
And "Earlier menopause can alter the quality of a woman's person and has profound implications for fertility, health and our society," senior study author Dr Amber Cooper, an subordinate professor of obstetrics and gynecology at Washington University School of Medicine in St Louis, said in a university low-down release. "Understanding how the environment affects constitution is complex. This study doesn't prove causation, but the associations raise a red gonfalon and support the need for future research".
In the study, Cooper's team analyzed blood and urine samples from more than 1400 menopausal women, averaging 61 years of age, to settle on their uncovering to 111 mostly man-made chemicals. According to the US Environmental Protection Agency, PCBs (polychlorinated biphenyls) have been banned in the United States since 1979, but can be found in items made before that time. Furans are by-products of industrial combustion, and phthalates are found in plastics, many household items, drugs and bodily responsibility products such as lotions, perfumes, makeup, secure polish, liquid soap and hair spray.
Extensive acquaintance to cheap chemicals appears to be linked to an earlier start of menopause, a new workroom suggests. Researchers found that menopause typically begins two to four years earlier in women whose bodies have intoxication levels of certain chemicals found in household items, personal care products, plastics and the environment, compared to women with diminish levels of the chemicals. The investigators identified 15 chemicals - nine (now banned) PCBs, three pesticides, two forms of plastics chemicals called phthalates, and the toxin furan - that were significantly associated with an earlier move of menopause and that may have unhealthy slang shit on ovarian function.
And "Earlier menopause can alter the quality of a woman's person and has profound implications for fertility, health and our society," senior study author Dr Amber Cooper, an subordinate professor of obstetrics and gynecology at Washington University School of Medicine in St Louis, said in a university low-down release. "Understanding how the environment affects constitution is complex. This study doesn't prove causation, but the associations raise a red gonfalon and support the need for future research".
In the study, Cooper's team analyzed blood and urine samples from more than 1400 menopausal women, averaging 61 years of age, to settle on their uncovering to 111 mostly man-made chemicals. According to the US Environmental Protection Agency, PCBs (polychlorinated biphenyls) have been banned in the United States since 1979, but can be found in items made before that time. Furans are by-products of industrial combustion, and phthalates are found in plastics, many household items, drugs and bodily responsibility products such as lotions, perfumes, makeup, secure polish, liquid soap and hair spray.
Thursday 19 March 2015
Another Layer Of Insight To The Placebo Effect
Another Layer Of Insight To The Placebo Effect.
A altered inspect - this one involving patients with Parkinson's disease - adds another layer of acuity to the well-known "placebo effect". That's the phenomenon in which people's symptoms improve after taking an listless substance simply because they believe the treatment will work. The small study, involving 12 people, suggests that Parkinson's patients seem to pet better - and their brains may actually change - if they meditate they're taking a costly medication. On average, patients had bigger short-term improvements in symptoms peer tremor and muscle stiffness when they were told they were getting the costlier of two drugs.
In reality, both "drugs" were nothing more than saline, given by injection. But the haunt patients were told that one drug was a new medication priced at $1500 a dose, while the other charge just $100 - though, the researchers assured them, the medications were expected to have alike effects. Yet, when patients' movement symptoms were evaluated in the hours after receiving the modify drugs, they showed greater improvements with the pricey placebo.
What's more, MRI scans showed differences in the patients' understanding activity, depending on which placebo they'd received. None of that is to mean that the patients' symptoms - or improvements - were "in their heads. Even a condition with objectively regulated signs and symptoms can improve because of the placebo effect," said Dr Peter LeWitt, a neurologist at Henry Ford West Bloomfield Hospital, in Michigan.
And that is "not classy to Parkinson's," added LeWitt, who wrote an essay published with the study that appeared online Jan 28, 2015 in the daily Neurology. Research has documented the placebo effect in various medical conditions. "The duct message here is that medication effects can be modulated by factors that consumers are not aware of - including perceptions of price". In the box of Parkinson's, it's thought that the placebo effect might shoot from the brain's release of the chemical dopamine, according to study leader Dr Alberto Espay, a neurologist at the University of Cincinnati College of Medicine.
A altered inspect - this one involving patients with Parkinson's disease - adds another layer of acuity to the well-known "placebo effect". That's the phenomenon in which people's symptoms improve after taking an listless substance simply because they believe the treatment will work. The small study, involving 12 people, suggests that Parkinson's patients seem to pet better - and their brains may actually change - if they meditate they're taking a costly medication. On average, patients had bigger short-term improvements in symptoms peer tremor and muscle stiffness when they were told they were getting the costlier of two drugs.
In reality, both "drugs" were nothing more than saline, given by injection. But the haunt patients were told that one drug was a new medication priced at $1500 a dose, while the other charge just $100 - though, the researchers assured them, the medications were expected to have alike effects. Yet, when patients' movement symptoms were evaluated in the hours after receiving the modify drugs, they showed greater improvements with the pricey placebo.
What's more, MRI scans showed differences in the patients' understanding activity, depending on which placebo they'd received. None of that is to mean that the patients' symptoms - or improvements - were "in their heads. Even a condition with objectively regulated signs and symptoms can improve because of the placebo effect," said Dr Peter LeWitt, a neurologist at Henry Ford West Bloomfield Hospital, in Michigan.
And that is "not classy to Parkinson's," added LeWitt, who wrote an essay published with the study that appeared online Jan 28, 2015 in the daily Neurology. Research has documented the placebo effect in various medical conditions. "The duct message here is that medication effects can be modulated by factors that consumers are not aware of - including perceptions of price". In the box of Parkinson's, it's thought that the placebo effect might shoot from the brain's release of the chemical dopamine, according to study leader Dr Alberto Espay, a neurologist at the University of Cincinnati College of Medicine.
Monday 16 March 2015
Traumatic Brain Injuries Of Some Veterans
Traumatic Brain Injuries Of Some Veterans.
The brains of some veterans of Iraq and Afghanistan who were injured by homemade bombs show an bizarre motif of damage, a small ruminate on finds. Researchers speculate that the damage - what they call a "honeycomb" pattern of broken and tumescent nerve fibers - might help explain the phenomenon of "shell shock". That style was coined during World War I, when trench warfare exposed troops to constant bombardment with exploding shells. Many soldiers developed an array of symptoms, from problems with view and hearing, to headaches and tremors, to confusion, appetite and nightmares.
Now referred to as blast neurotrauma, the injuries have become an effective issue again, said Dr Vassilis Koliatsos, the senior researcher on the new study. "Vets coming back from Iraq and Afghanistan have been exposed to a type of situations, including blasts from improvised chancy devices IEDs ," said Koliatsos, a professor of pathology, neurology and psychiatry at Johns Hopkins University in Baltimore.
But even though the cognizance of shell shock goes back 100 years, researchers still positive little about what is actually going on in the brain. For the new study, published recently in the annual Acta Neuropathologica Communications, his team studied autopsied brain tissue from five US grapple veterans. The soldiers had all survived IED bomb blasts, but later died of other causes. The researchers compared the vets' percipience tissue to autopsies of 24 commoners who had died of various causes, including traffic accidents and drug overdoses.
The soldiers' brains showed a plain pattern of damage to nerve fibers in key regions of the brain - including the frontal lobes, which hold the whip hand memory, reasoning and decision-making. He said the "honeycomb" mould of small lesions was unlike the damage seen in people who died from head trauma in a car accident, or those who suffered "punch-drunk syndrome" - acumen degeneration caused by repeated concussions.
The brains of some veterans of Iraq and Afghanistan who were injured by homemade bombs show an bizarre motif of damage, a small ruminate on finds. Researchers speculate that the damage - what they call a "honeycomb" pattern of broken and tumescent nerve fibers - might help explain the phenomenon of "shell shock". That style was coined during World War I, when trench warfare exposed troops to constant bombardment with exploding shells. Many soldiers developed an array of symptoms, from problems with view and hearing, to headaches and tremors, to confusion, appetite and nightmares.
Now referred to as blast neurotrauma, the injuries have become an effective issue again, said Dr Vassilis Koliatsos, the senior researcher on the new study. "Vets coming back from Iraq and Afghanistan have been exposed to a type of situations, including blasts from improvised chancy devices IEDs ," said Koliatsos, a professor of pathology, neurology and psychiatry at Johns Hopkins University in Baltimore.
But even though the cognizance of shell shock goes back 100 years, researchers still positive little about what is actually going on in the brain. For the new study, published recently in the annual Acta Neuropathologica Communications, his team studied autopsied brain tissue from five US grapple veterans. The soldiers had all survived IED bomb blasts, but later died of other causes. The researchers compared the vets' percipience tissue to autopsies of 24 commoners who had died of various causes, including traffic accidents and drug overdoses.
The soldiers' brains showed a plain pattern of damage to nerve fibers in key regions of the brain - including the frontal lobes, which hold the whip hand memory, reasoning and decision-making. He said the "honeycomb" mould of small lesions was unlike the damage seen in people who died from head trauma in a car accident, or those who suffered "punch-drunk syndrome" - acumen degeneration caused by repeated concussions.
Saturday 14 March 2015
Years Of Attempts To Quit Smoking
Years Of Attempts To Quit Smoking.
Quitting smoking is notoriously tough, and some smokers may evaluate novel approaches for years before they succeed, if ever. But novel research suggests that someday, a simple test might point smokers toward the quitting strategy that's best for them. It's been dream of theorized that some smokers are genetically predisposed to process and rid the body of nicotine more at than others. And now a new study suggests that slower metabolizers seeking to punt the habit will probably have a better treatment experience with the aid of a nicotine patch than the quit-smoking drug varenicline (Chantix). The decree is based on the tracking of more than 1200 smokers undergoing smoking-cessation treatment.
Blood tests indicated that more than 660 were comparatively slow nicotine metabolizers, while the rest were normal nicotine metabolizers. Over an 11-week trial, participants were prescribed a nicotine patch, Chantix, or a non-medicinal "placebo". As reported online Jan 11, 2015 in The Lancet Respiratory Medicine, stable metabolizers fared better using the treatment compared with the nicotine patch. Specifically, 40 percent of general metabolizers who were given the poison option were still not smoking at the end of their treatment, the study found.
This compared with just 22 percent who had been given a nicotine patch. Among the slow-metabolizing group, both treatments worked equally well at ration smokers quit, the researchers noted. However, compared with those treated with the nicotine patch, tortoise-like metabolizers treated with Chantix knowledgeable more side effects. This led the yoke to conclude that slow metabolizers would fare better - and likely remain cigarette-free - when using the patch.
Quitting smoking is notoriously tough, and some smokers may evaluate novel approaches for years before they succeed, if ever. But novel research suggests that someday, a simple test might point smokers toward the quitting strategy that's best for them. It's been dream of theorized that some smokers are genetically predisposed to process and rid the body of nicotine more at than others. And now a new study suggests that slower metabolizers seeking to punt the habit will probably have a better treatment experience with the aid of a nicotine patch than the quit-smoking drug varenicline (Chantix). The decree is based on the tracking of more than 1200 smokers undergoing smoking-cessation treatment.
Blood tests indicated that more than 660 were comparatively slow nicotine metabolizers, while the rest were normal nicotine metabolizers. Over an 11-week trial, participants were prescribed a nicotine patch, Chantix, or a non-medicinal "placebo". As reported online Jan 11, 2015 in The Lancet Respiratory Medicine, stable metabolizers fared better using the treatment compared with the nicotine patch. Specifically, 40 percent of general metabolizers who were given the poison option were still not smoking at the end of their treatment, the study found.
This compared with just 22 percent who had been given a nicotine patch. Among the slow-metabolizing group, both treatments worked equally well at ration smokers quit, the researchers noted. However, compared with those treated with the nicotine patch, tortoise-like metabolizers treated with Chantix knowledgeable more side effects. This led the yoke to conclude that slow metabolizers would fare better - and likely remain cigarette-free - when using the patch.
Sunday 1 March 2015
A New Antibiotic For Fighting Disease-Causing Bacteria
A New Antibiotic For Fighting Disease-Causing Bacteria.
Laboratory researchers roughly they've discovered a additional antibiotic that could prove valuable in fighting disease-causing bacteria that no longer answer to older, more frequently used drugs. The new antibiotic, teixobactin, has proven true against a number of bacterial infections that have developed resistance to existing antibiotic drugs, researchers write-up in Jan 7, 2015 in the journal Nature. Researchers have used teixobactin to prescription lab mice of MRSA (methicillin-resistant Staphylococcus aureus), a bacterial infection that sickens 80000 Americans and kills 11000 every year, according to the US Centers for Disease Control and Prevention (CDC).
The creative antibiotic also worked against the bacteria that causes pneumococcal pneumonia. Cell enlightenment tests also showed that the uncharted drug effectively killed off drug-resistant strains of tuberculosis, anthrax and Clostridium difficile, a bacteria that causes life-threatening diarrhea and is associated with 250000 infections and 14000 deaths in the United States each year, according to the CDC. "My appraise is that we will unquestionably be in clinical trials three years from now," said the study's elder author, Kim Lewis, director of the Antimicrobial Discovery Center at Northeastern University in Boston.
Lewis said researchers are working to focus the inexperienced antibiotic and make it more effective for use in humans. Dr Ambreen Khalil, an infectious disease connoisseur at Staten Island University Hospital in New York City, said teixobactin "has the covert of being a valuable addition to a limited number of antibiotic options that are currently available". In particular, its effectiveness against MRSA "may corroborate to be critically significant".
And its potent activity against C difficile also "makes it a propitious compound at this time". Most antibiotics are created from bacteria found in the soil, but only about 1 percent of these microorganisms will blossom in petri dishes in laboratories. Because of this, it's become increasingly fussy to find new antibiotics in nature. The 1960s heralded the end of the original era of antibiotic discovery, and synthetic antibiotics were unable to replace natural products, the authors said in distance notes.
Laboratory researchers roughly they've discovered a additional antibiotic that could prove valuable in fighting disease-causing bacteria that no longer answer to older, more frequently used drugs. The new antibiotic, teixobactin, has proven true against a number of bacterial infections that have developed resistance to existing antibiotic drugs, researchers write-up in Jan 7, 2015 in the journal Nature. Researchers have used teixobactin to prescription lab mice of MRSA (methicillin-resistant Staphylococcus aureus), a bacterial infection that sickens 80000 Americans and kills 11000 every year, according to the US Centers for Disease Control and Prevention (CDC).
The creative antibiotic also worked against the bacteria that causes pneumococcal pneumonia. Cell enlightenment tests also showed that the uncharted drug effectively killed off drug-resistant strains of tuberculosis, anthrax and Clostridium difficile, a bacteria that causes life-threatening diarrhea and is associated with 250000 infections and 14000 deaths in the United States each year, according to the CDC. "My appraise is that we will unquestionably be in clinical trials three years from now," said the study's elder author, Kim Lewis, director of the Antimicrobial Discovery Center at Northeastern University in Boston.
Lewis said researchers are working to focus the inexperienced antibiotic and make it more effective for use in humans. Dr Ambreen Khalil, an infectious disease connoisseur at Staten Island University Hospital in New York City, said teixobactin "has the covert of being a valuable addition to a limited number of antibiotic options that are currently available". In particular, its effectiveness against MRSA "may corroborate to be critically significant".
And its potent activity against C difficile also "makes it a propitious compound at this time". Most antibiotics are created from bacteria found in the soil, but only about 1 percent of these microorganisms will blossom in petri dishes in laboratories. Because of this, it's become increasingly fussy to find new antibiotics in nature. The 1960s heralded the end of the original era of antibiotic discovery, and synthetic antibiotics were unable to replace natural products, the authors said in distance notes.
Subscribe to:
Posts (Atom)